Trials / Completed
CompletedNCT03893591
A Prospective Study to Examine the Need to Adjust the Dose of Apixaban When Used in Atrial Fibrillation and Obesity
A Prospective Cohort Study to Examine the Need to Adjust the Dose of Anticoagulant Apixaban When Used in Patients With Atrial Fibrillation and Obesity
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 82 (actual)
- Sponsor
- HaEmek Medical Center, Israel · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
A prospective cohort study to determine whether a high body weight (BMI equal to or greater than 35 kg / m 2) has an effect on anticoagulant Apixaban level in the blood of patients with atrial fibrillation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Anti Xa levels | one Blood sample |
Timeline
- Start date
- 2019-05-06
- Primary completion
- 2020-02-29
- Completion
- 2020-02-29
- First posted
- 2019-03-28
- Last updated
- 2020-04-01
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT03893591. Inclusion in this directory is not an endorsement.